A European Commission official told Inside Health Policy this week that drug pricing policy choices in the United States are responsible for high prices, not “global freeloading,” as President Donald Trump said when he unveiled a new payment model for prescription drugs in Medicare Part B that relies on international reference pricing. HHS Secretary Alex Azar said in a speech after the model was announced that if drug companies were worried about their research and development budgets, that they...